Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Photo: Andrew Harrer/Bloomberg via Getty Images

The White House announced Friday that the federal government will invest $1.7 billion in funding from the American Rescue Plan to "improve the detection, monitoring, and mitigation" of COVID-19 variants.

Why it matters: New and dangerous virus strains make up half of all cases in America today and risk prolonging the pandemic. Some are more contagious than the original virus.

By the numbers: $1 billion in funding will expand genomic sequencing so states and localities can better detect and track variants.

  • $400 million will go toward innovation initiatives, including the launch of six Centers of Excellence in Genomic Epidemiology, to develop surveillance methods for tracking pathogens and fuel "cutting-edge research" on genomic epidemiology.
  • $300 million will be allocated to help build out and support a National Bioinformatics Infrastructure that can collect data and help experts "connect the dots between how pathogens spread and mutate to help solve outbreaks."

The big picture: At a briefing Friday, top health officials maintained the importance of continuing to vaccinate despite concerns about Johnson & Johnson's vaccine.

Go deeper: Explore Axios' live variant tracker

Go deeper

Updated 10 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

J&J vaccine pause hurts its reputation

Reproduced from Economist/YouGov poll; Chart: Axios Visuals

Americans' confidence in the safety of Johnson & Johnson's coronavirus vaccine took a big dip this week after the pause in its use, per new YouGov polling, even though the risk of blood clots following the shot is extremely low, if it exists at all.

Why it matters: For the majority of people, particularly high-risk Americans, getting the J&J shot is almost certainly less dangerous than remaining vulnerable to the coronavirus.

Apr 16, 2021 - Health

Winning the war on COVID is good for insurers

A pharmacy student administering a coronavirus vaccine to another student at Florida International University on April 15 in Miami. Photo: Joe Raedle/Getty Images

A Wall Street Journal piece on UnitedHealth's quarterly results shows a first-quarter profit that was better than expected.

Driving the news: That profit was driven in part by the fact that its COVID costs declined — and the company now expects to do better for the rest of the year too, the Journal reports.